Strategies for Predicting Response to Checkpoint Inhibitors

Current Hematologic Malignancy Reports
Roberta ZappasodiTaha Merghoub

Abstract

Despite the clinical successes of immune checkpoint blockade across multiple tumor types, many patients do not respond to these therapies or become resistant after an initial response. This underscores the need to improve our understanding of the molecular determinants of response to guide more personalized and rational utilization of these therapies. Here, we describe available biomarkers of checkpoint blockade activity by classifying them into four major categories: tumor-intrinsic, immune microenvironmental, host-related, and dynamic factors. The clinical experience accumulated thus far with checkpoint blockade now offers the opportunity to comprehensively study the molecular and immune features associated with response. This is yielding a growing set of biomarkers whose integration will be key to more accurately predict clinical outcome. We propose a model for systematic assessment of available baseline and dynamic biomarkers in relationship with patients' outcomes. This will improve our understanding of the tumor-immune interactions and dynamics that predict a clinical response and will provide key information to develop more personalized and effective treatment strategies.

References

Mar 22, 1996·Science·D R LeachJ P Allison
Jan 1, 1997·Annual Review of Immunology·E A BachR D Schreiber
Mar 23, 2004·Annual Review of Immunology·Gavin P DunnRobert D Schreiber
Apr 19, 2005·Cancer Research·Gavin P DunnRobert D Schreiber
Apr 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuichiro OhigashiYoshiyuki Nakajima
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Dec 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Michal MarzecMariusz A Wasik
Sep 25, 2009·Nature Reviews. Cancer·Arnold J Levine, Moshe Oren
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck PagèsJérôme Galon
May 13, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bradley C CarthonPadmanee Sharma
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Jul 7, 2011·Nature Structural & Molecular Biology·William K Holloman
Dec 8, 2011·Cancer Immunology, Immunotherapy : CII·Rui-Ru JiVafa Shahabi
Mar 16, 2012·Nature Reviews. Cancer·Wolf Herman FridmanJérôme Galon
Jul 14, 2012·Journal of Translational Medicine·Wenshi WangJeffrey S Weber
Jan 5, 2013·Journal of Hematology & Oncology·James D MellorAlexander Dobrovic
Jan 16, 2013·Cell Reports·Ludmil B AlexandrovMichael R Stratton
Jul 31, 2013·The Journal of Experimental Medicine·Yannick BulliardJennifer L Brogdon
Mar 4, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lidia RobertAntoni Ribas
Apr 30, 2014·Cancer Immunology Research·Derek Ng TangPadmanee Sharma
May 30, 2014·Science Translational Medicine·Edward ChaLawrence Fong
Sep 14, 2014·Molecular Cancer Research : MCR·Eleanor N Fish, Leonidas C Platanias
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Nov 22, 2014·Nucleic Acids Research·James RobinsonSteven G E Marsh
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Apr 29, 2015·Proceedings of the National Academy of Sciences of the United States of America·Emanuela RomanoDaniel E Speiser
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel

❮ Previous
Next ❯

Citations

Dec 24, 2018·International Journal of Molecular Sciences·Florian WirsdörferVerena Jendrossek
Apr 4, 2020·Nature Reviews. Clinical Oncology·Maria-Elisabeth Goebeler, Ralf C Bargou
Aug 3, 2019·Cancer Immunology Research·Alexander M LesokhinAshraf Z Badros
Aug 17, 2021·Radiologic Clinics of North America·Christian MasonJason S Lewis
Sep 5, 2021·The Journal of Pathology. Clinical Research·Sze-Hwei LeeHwei-Fang Tien

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

© 2022 Meta ULC. All rights reserved